Nasdaq · CIK 0001253689
CBIO CRESCENT BIOPHARMA, INC.
Insider trading from SEC Form 4. Last filing 24 d ago. Close $14.91 on Oct 9, 2026, +67% from the 52-week low and -45% from the high.
Last 90 days
Net insider value
-$286k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
7
$286k by 7 insiders
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
CBIOOct 9, 2026 · close 14.91
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at CRESCENT BIOPHARMA, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | Barbara Harlin Bispham See Remarks sell | $11k 620 shares | -3% | - | |
| 31Weak | Joshua T Brumm Chief Executive Officer sell | $160k 9,447 shares | -3% | - | |
| 23Weak | Jonathan McNeill President and COO sell | $77k 4,570 shares | -3% | - | |
| 17Weak | Richard William Scalzo Chief Financial Officer sell | $10k 568 shares | -3% | - | |
| 10Weak | Ellie Eunkyung Im Chief Medical Officer sell | $11k 623 shares | -3% | - | |
| 10Weak | Jan Pinkas Chief Scientific Officer sell | $12k 658 shares | -3% | - | |
| 10Weak | Ryan Lynch See Remarks sell | $4,296 240 shares | -2% | - |
Transactions
The last 21 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | Barbara Harlin Bispham See Remarks | SOpen-market sale Ordinary Shares10b5-1 | -620 | $17.90 | $11k | 18,710 | 24 d ago |
| Sep 16, 2026 | Joshua T Brumm Chief Executive Officer | SOpen-market sale Ordinary Shares10b5-1 | -1,610 | $17.90 | $29k | 279,602 | 24 d ago |
| Sep 16, 2026 | Jonathan McNeill President and COO | SOpen-market sale Ordinary Shares10b5-1 | -731 | $17.90 | $13k | 138,427 | 24 d ago |
| Sep 16, 2026 | Richard William Scalzo Chief Financial Officer | SOpen-market sale Ordinary Shares10b5-1 | -568 | $17.90 | $10k | 19,730 | 24 d ago |
| Sep 16, 2026 | Ellie Eunkyung Im Chief Medical Officer | SOpen-market sale Ordinary Shares10b5-1 | -623 | $17.90 | $11k | 21,446 | 24 d ago |
| Sep 16, 2026 | Jan Pinkas Chief Scientific Officer | SOpen-market sale Ordinary Shares10b5-1 | -658 | $17.90 | $12k | 21,581 | 24 d ago |
| Sep 16, 2026 | Ryan Lynch See Remarks | SOpen-market sale Ordinary Shares10b5-1 | -240 | $17.90 | $4,296 | 13,631 | 24 d ago |
| Sep 18, 2026 | Jonathan McNeill President and COO | SOpen-market sale Ordinary Shares10b5-1 | -3,839 | $16.71 | $64k | 134,588 | 24 d ago |
| Sep 18, 2026 | Joshua T Brumm Chief Executive Officer | SOpen-market sale Ordinary Shares10b5-1 | -7,837 | $16.71 | $131k | 271,765 | 24 d ago |
| Jul 16, 2025 | Jan Pinkas Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +142,474 | $0.00 | $0 | 142,474 | Jul 16, 2025 |
| Jun 23, 2025 | Alexandra Balcom director | AGrant or award Stock Option (Right to Buy)derivative | +9,023 | $0.00 | $0 | 9,023 | Jun 23, 2025 |
| Jun 23, 2025 | Susan Moran director | AGrant or award Stock Option (Right to Buy)derivative | +9,023 | $0.00 | $0 | 9,023 | Jun 23, 2025 |
| Jun 23, 2025 | Jonathan Violin director | AGrant or award Stock Option (Right to Buy)derivative | +9,023 | $0.00 | $0 | 9,023 | Jun 23, 2025 |
| Jun 23, 2025 | David Charles Lubner director | AGrant or award Stock Option (Right to Buy)derivative | +9,023 | $0.00 | $0 | 9,023 | Jun 23, 2025 |
| Jun 23, 2025 | Fairmount Funds Management LLC director, owner | AGrant or award Stock Option (Right to Buy)derivativeindirect: By: Peter Harwin | +9,023 | $0.00 | $0 | 9,023 | Jun 23, 2025 |
| Jun 13, 2025 | Bvf Partners L P/il owner | JOther Common Stock | +657,308 | - | - | 707,116 | Jun 17, 2025 |
| Jun 13, 2025 | Bvf Partners L P/il owner | JOther Common Stock | +556,617 | - | - | 593,740 | Jun 17, 2025 |
| Jun 13, 2025 | Bvf Partners L P/il owner | JOther Common Stock | +56,079 | - | - | 62,383 | Jun 17, 2025 |
| Jun 13, 2025 | Bvf Partners L P/il owner | JOther Pre-Funded Warrants to Purchase Common Stockderivative | +304,098 | - | - | 304,098 | Jun 17, 2025 |
| Jun 13, 2025 | Bvf Partners L P/il owner | JOther Pre-Funded Warrants to Purchase Common Stockderivative | +257,515 | - | - | 257,515 | Jun 17, 2025 |
| Jun 13, 2025 | Bvf Partners L P/il owner | JOther Pre-Funded Warrants to Purchase Common Stockderivative | +25,944 | - | - | 25,944 | Jun 17, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Bvf Partners L P/ilother, owner, director
- Alexandra Balcomcfo, officer, director
- Barbara Harlin BisphamSee Remarks
- Joshua T BrummChief Executive Officer
- Fairmount Funds Management LLCdirector, owner
- Ellie Eunkyung ImChief Medical Officer
- David Charles Lubnerdirector
- Ryan LynchSee Remarks
- Jonathan McNeillPresident and COO
- Susan Morandirector
- Jan PinkasChief Scientific Officer
- Richard William ScalzoChief Financial Officer
- Jonathan Violindirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.